BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Eby JM, Kang HK, Klarquist J, Chatterjee S, Mosenson JA, Nishimura MI, Garrett-Mayer E, Longley BJ, Engelhard VH, Mehrotra S, Le Poole IC. Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation. Pigment Cell Melanoma Res 2014;27:1075-85. [PMID: 24935676 DOI: 10.1111/pcmr.12284] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Mukhatayev Z, Ostapchuk YO, Fang D, Le Poole IC. Engineered antigen-specific regulatory T cells for autoimmune skin conditions. Autoimmun Rev 2021;20:102761. [PMID: 33476816 DOI: 10.1016/j.autrev.2021.102761] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Speeckaert R, Mylle S, van Geel N. IL-17A is not a treatment target in progressive vitiligo. Pigment Cell Melanoma Res 2019;32:842-7. [PMID: 31063266 DOI: 10.1111/pcmr.12789] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
3 Mukhatayev Z, Dellacecca ER, Cosgrove C, Shivde R, Jaishankar D, Pontarolo-Maag K, Eby JM, Henning SW, Ostapchuk YO, Cedercreutz K, Issanov A, Mehrotra S, Overbeck A, Junghans RP, Leventhal JR, Le Poole IC. Antigen Specificity Enhances Disease Control by Tregs in Vitiligo. Front Immunol 2020;11:581433. [PMID: 33335528 DOI: 10.3389/fimmu.2020.581433] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Chai Y, Huang Y, Tang H, Tu X, He J, Wang T, Zhang Q, Xiong F, Li D, Qiu Z. Role of stem cell growth factor/c-Kit in the pathogenesis of irritable bowel syndrome. Exp Ther Med 2017;13:1187-93. [PMID: 28413456 DOI: 10.3892/etm.2017.4133] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
5 Wang X, Li K, Liu L, Shi Q, Song P, Jian Z, Guo S, Wang G, Li C, Gao T. AHR promoter variant modulates its transcription and downstream effectors by allele-specific AHR-SP1 interaction functioning as a genetic marker for vitiligo. Sci Rep 2015;5:13542. [PMID: 26370050 DOI: 10.1038/srep13542] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
6 Le Poole IC, Mehrotra S. Replenishing Regulatory T Cells to Halt Depigmentation in Vitiligo. J Investig Dermatol Symp Proc 2017;18:S38-45. [PMID: 28941492 DOI: 10.1016/j.jisp.2016.10.023] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
7 Dwivedi M, Kemp EH, Laddha NC, Mansuri MS, Weetman AP, Begum R. Regulatory T cells in vitiligo: Implications for pathogenesis and therapeutics. Autoimmun Rev 2015;14:49-56. [PMID: 25308528 DOI: 10.1016/j.autrev.2014.10.002] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 8.3] [Reference Citation Analysis]
8 Goldstein NB, Koster MI, Jones KL, Gao B, Hoaglin LG, Robinson SE, Wright MJ, Birlea SI, Luman A, Lambert KA, Shellman YG, Fujita M, Robinson WA, Roop DR, Norris DA, Birlea SA. Repigmentation of Human Vitiligo Skin by NBUVB Is Controlled by Transcription of GLI1 and Activation of the β-Catenin Pathway in the Hair Follicle Bulge Stem Cells. J Invest Dermatol 2018;138:657-68. [PMID: 29054607 DOI: 10.1016/j.jid.2017.09.040] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
9 Goldstein NB, Steel A, Barbulescu CC, Koster MI, Wright MJ, Jones KL, Gao B, Ward B, Woessner B, Trottier Z, Pakieser J, Hu J, Lambert KA, Shellman YG, Fujita M, Robinson WA, Roop DR, Norris DA, Birlea SA. Melanocyte Precursors in the Hair Follicle Bulge of Repigmented Vitiligo Skin Are Controlled by RHO-GTPase, KCTD10, and CTNNB1 Signaling. J Invest Dermatol 2021;141:638-647.e13. [PMID: 32800877 DOI: 10.1016/j.jid.2020.07.016] [Reference Citation Analysis]
10 Czarnowicki T, He H, Leonard A, Kim HJ, Kameyama N, Pavel AB, Li R, Estrada Y, Wen H, Kimmel GW, Kim HJ, Chima M, Lebwohl M, Krueger JG, Guttman-yassky E. Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases. Journal of Allergy and Clinical Immunology 2019;143:2095-107. [DOI: 10.1016/j.jaci.2018.11.031] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
11 Singh RK, Lee KM, Vujkovic-Cvijin I, Ucmak D, Farahnik B, Abrouk M, Nakamura M, Zhu TH, Bhutani T, Wei M, Liao W. The role of IL-17 in vitiligo: A review. Autoimmun Rev 2016;15:397-404. [PMID: 26804758 DOI: 10.1016/j.autrev.2016.01.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 8.3] [Reference Citation Analysis]
12 Kemp EH. Programmed death 1 expressing regulatory T cells in vitiligo. Br J Dermatol 2015;172:847-8. [PMID: 25827728 DOI: 10.1111/bjd.13595] [Reference Citation Analysis]
13 Speeckaert R, Lambert J, Grine L, Van Gele M, De Schepper S, van Geel N. The many faces of interleukin-17 in inflammatory skin diseases. Br J Dermatol 2016;175:892-901. [PMID: 27117954 DOI: 10.1111/bjd.14703] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 8.2] [Reference Citation Analysis]